NEW YORK (GenomeWeb News) – Metamark Genetics today announced that Massachusetts has licensed the company's laboratory as it prepares to launch its prognostic assay for managing patients with prostate cancer.

The lab in Cambridge, Mass. is CLIA-certified, but a handful of states require additional regulatory approval before certain tests can be performed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.